Mattsson, N;
Groot, C;
Jansen, WJ;
Landau, SM;
Villemagne, VL;
Engelborghs, S;
Mintun, MM;
... Ossenkoppele, R; + view all
(2018)
Prevalence of the apolipoprotein E epsilon 4 allele in amyloid beta positive subjects across the spectrum of Alzheimer's disease.
Alzheimer's and Dementia
, 14
(7)
pp. 913-924.
10.1016/j.jalz.2018.02.009.
Preview |
Text
Zetterberg_Mattsson.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Introduction: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology. Methods: We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location. Results: The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P < .05) but not in Aβ+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education. Discussion: The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
Type: | Article |
---|---|
Title: | Prevalence of the apolipoprotein E epsilon 4 allele in amyloid beta positive subjects across the spectrum of Alzheimer's disease |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1016/j.jalz.2018.02.009 |
Publisher version: | http://doi.org/10.1016/j.jalz.2018.02.009 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | APOE; Prevalence; Amyloid; PET; CSF; Alzheimer’s disease; Mild cognitive impairment; Subjective cognitivedecline; Age; Sex; Education; Geographical location |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10064637 |
Archive Staff Only
View Item |